GSK Q3 Earnings Top, Stock Down on Lowered '24 View for Vaccine Sales

GSK plc (GSK) reported third-quarter 2024 core earnings of $1.27 per American depositary share (ADS), which beat the Zacks Consensus Estimate of$1.16. Core earnings declined 1% year over year on a reported basis but rose 5% at a constant exchange rate (CER). Quarterly revenues fell 2% on a reported basis but rose 2% at CER to $10.42 billion (£8.01 billion). The top line missed the Zacks Consensus Estimate of$10.65 billion. This was due to lower sales of RSV and shingles vaccines in the United States. All ...